English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/168631
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
DC FieldValueLanguage
dc.contributor.authorHerrero, Ana B.-
dc.contributor.authorRojas, Elizabeta A.-
dc.contributor.authorMisiewicz-Krzeminska, Irena-
dc.contributor.authorKrzemiński, Patryk-
dc.contributor.authorGutiérrez, Norma Carmen-
dc.date.accessioned2018-08-13T10:27:20Z-
dc.date.available2018-08-13T10:27:20Z-
dc.date.issued2016-
dc.identifierdoi: 10.3390/ijms17122003-
dc.identifiere-issn: 1422-0067-
dc.identifierissn: 1661-6596-
dc.identifier.citationInternational Journal of Molecular Sciences 17(12): 2003 (2016)-
dc.identifier.urihttp://hdl.handle.net/10261/168631-
dc.descriptionThis article belongs to the Special Issue Emerging Non-Canonical Functions and Regulation of p53.-
dc.description.abstractThe p53 pathway is inactivated in the majority of human cancers. Although this perturbation frequently occurs through the mutation or deletion of p53 itself, there are other mechanisms that can attenuate the pathway and contribute to tumorigenesis. For example, overexpression of important p53 negative regulators, such as murine double minute 2 (MDM2) or murine double minute 4 (MDM4), epigenetic deregulation, or even alterations in TP53 mRNA splicing. In this work, we will review the different mechanisms of p53 pathway inhibition in cancer with special focus on multiple myeloma (MM), the second most common hematological malignancy, with low incidence of p53 mutations/deletions but growing evidence of indirect p53 pathway deregulation. Translational implications for MM and cancer prognosis and treatment are also reviewed.-
dc.description.sponsorshipThis study was partially supported by the Instituto de Salud Carlos III-Cofinanciación con fondos FEDER (PI16/01074), the Gerencia Regional de Salud, Junta de Castilla y León (1344/A/16) grants, and the INNOCAM-PUS Program (CEI10-1-0010).-
dc.publisherMultidisciplinary Digital Publishing Institute-
dc.relation.isversionofPublisher's version-
dc.rightsopenAccess-
dc.subjectTP53 methylation-
dc.subjectp53-based therapy-
dc.subjectmiRNAs-
dc.subjectTP53 splicing-
dc.subjectEpigenetics-
dc.subjectTP53 mutations-
dc.subjectCancer-
dc.subjectMyeloma-
dc.subjectp53-
dc.titleMolecular mechanisms of p53 deregulation in cancer: An overview in multiple myeloma-
dc.typeartículo-
dc.date.updated2018-08-13T10:27:21Z-
dc.description.versionPeer Reviewed-
dc.language.rfc3066eng-
dc.rights.licensehttp://creativecommons.org/licenses/by/4.0/-
dc.contributor.funderEuropean Commission-
dc.contributor.funderJunta de Castilla y León-
dc.contributor.funderInstituto de Salud Carlos III-
dc.relation.csic-
dc.identifier.funderhttp://dx.doi.org/10.13039/501100004587es_ES
dc.identifier.funderhttp://dx.doi.org/10.13039/501100000780es_ES
dc.identifier.pmid27916892-
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
molmyel.pdf714,12 kBAdobe PDFThumbnail
View/Open
Show simple item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.